Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma GmbH
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study to assess the efficacy and safety of QVA149 in patients with COPD
To demonstrate non-inferiority of QVA149 110/50 µg to tiotropium 18 µg q.d. plus formoterol 12µg b.i.d. in terms of health related quality of life as assessed by St George’s Respiratory Questionnaire ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-dependent iron overload
The primary objective of this study is to evaluate if fixed starting doses of ICL670, dependent on transfusion history, and subsequent dose titration can provide clinically acceptable chelation among ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study of efficacy and safety of LEE011 ribociclib (LEE011) in combination with letrozole in patients with advanced breast cancer
To assess the clinical benefit rate (CBR) after 24 weeks for ribociclib (LEE011) in combination with letrozole among postmenopausal women and men with hormone receptor positive, HER2- negative, advanc...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Comparison of safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus
1. To demonstrate that add-on to glimeperide vildagliptin is superior to NPH insulin with respect to the incidence of the combined endpoint, defined as a blood glucose target (HbA1c below 7.0%) withou...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Extension study to the expanded access study of everolimus in patients with advanced neuroendocrine tumors
To evaluate long-term safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal or pulmonary origin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Comparison of the glycemic profiles of vildagliptin and sitagliptin treatment in type-2 diabetic patients
To demonstrate that vildagliptin leads to a favorable hypoglycemic profile compared to sitagliptin, after 8 weeks of treatment, each, when used in combination with insulin. The hypoglycemic profile wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300mg BID
To evaluate the proportion of patients who are in deep molecular response MR4.5 (IS) at 24 months of study treatment, measured in a standardized EUTOS MR4.5 laboratory.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cystic Fibrosis (CF) Subjects
To evaluate the serum pharmacokinetics (PK) of inhaled TOBI® (AUC0-90’) of continuous daily dosing regimens with 2x300mg/d Tobramycin Nebulised Solution (=TNS) inhaled with the PARI eFlow® rapid in Cy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST
To assess the response to treatment with RAD001 plus Glivec® at 4 months. Response is defined as progression-free survival (PFS) at 4 months.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis
To prove superiority of zoledronic acid compared to alendronate by testing the hypothesis that the change of the level of NTx in serum within the first 12 months after start of therapy in postmenopaus...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next